Noticias y Actividades de Eagle Pharmaceuticals

Eagle Pharmaceuticals es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Eagle Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización EGRX (US).

Fusión, adquisición y financiación con participación de Eagle Pharmaceuticals.

• Revelation Pharma has announced the acquisition of Eagle Pharmaceuticals  (publicado el 24 de julio de 2023).

Ver el organigrama con sus 9 ejecutivos principales

Biografías más buscadas en Eagle Pharmaceuticals

• Michael Graves, Interim Executive Chairman of the Board
• Robert Glenning, Director
• Richard Edlin, Director

Recientes movimientos de ejecutivos en Eagle Pharmaceuticals

• Christopher Krawtschuk, se ha incorporado a la empresa como Chief Financial Officer and Director  (noticia publicada el 13 de noviembre de 2024).

Crear su alerta
para seguir los movimientos de los ejecutivos en Eagle Pharmaceuticals.

Eagle Pharmaceuticals tiene 1.833 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).

Popular M&A news in Farmacia

• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
• Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado el 12 de marzo de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Paul Meister - Chairman of the Board en Amneal Pharmaceuticals

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Eagle Pharmaceuticals

• Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation | Eagle Pharmaceuticals Investor Center
• Press Releases | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020 | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ (Pemetrexed for Injection) | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke | Eagle Pharmaceuticals Investor Center
• Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury | Eagle Pharmaceuticals Investor Center
• Press Releases | Eagle Pharmaceuticals Investor Center
• View more press releases Close

Redes sociales sobre Eagle Pharmaceuticals

• Eagle Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Eagle Pharmaceuticals en LinkedIn, Twitter y YouTube